Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 4 1

Status

Terminated 2Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Gynecologic 1

Conditions

Breast Neoplasms 219Neoplasms 15Neoplasm Metastasis 12Carcinoma, Intraductal, Noninfiltrating 10Breast Neoplasms, Male 7Breast Diseases 7Breast Carcinoma In Situ 7Advanced Breast Cancer 6Triple Negative Breast Neoplasms 5Ovarian Neoplasms 5Endometrial Neoplasms 5Neoplasms by Site 3Breast Cancer Metastatic 3Uterine Cervical Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasm Female 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Seizures 1Sarcoma 1Recurrence 1Quality of Life 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteoporosis 1Multiple Endocrine Neoplasia Type 1 1Low Grade Serous Ovarian Cancer 1

Interventions

pembrolizumab 160Carboplatin 143Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 37Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × Anastrozole × Clear all
NCT04556773 2025-12-17

DB-08

AstraZeneca

Phase 1 Active not recruiting
138 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Completed
30 enrolled 11 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01234532 2022-05-03

0927GCC

University of Maryland, Baltimore

Phase 2 Terminated
5 enrolled 7 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02089854 2016-12-02

AETNBC

Peking Union Medical College Hospital

Phase 4 Unknown
800 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡